‘Immune Thrombocytopenia (ITP)- Epidemiology Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends of Immune Thrombocytopenia (ITP) Infections in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Most of children with newly diagnosed ITP will develop chronic disease. Because of the high impact of ITP on a child's everyday life and activities, as well as to decide whether treatment has to be instituted to influence the clinical course of ITP, it is of clinical significance if the course of the disease could be predicted at time of diagnosis.
Our forecasting model has defined the prevalent population of Chronic Immune Thrombocytopenia (ITP) in children & adults. Chronic ITP patient inclusive of both primary ITP and secondary ITP. Approximately 70-75% of patient are refractory to first line therapies (corticosteroids/IVIG & others) and take second line therapies. As per the analysis, we have found that approximately 60-65% patients are refractory to second line treatment and take third line treatment.
Geography Covered
Immune thrombocytopenia (ITP) - Disease Understanding
Immune thrombocytopenia (ITP), previously called immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder that occurs when the body attacks its own platelets and destroys them too quickly. ITP is a disorder that affects the overall number of blood platelets rather than their function.
Immune thrombocytopenia (ITP) is also categorized as primary and secondary based on the cause of the disease. ITP in the absence of other causes or disorders that may be associated with the thrombocytopenia is known as primary ITP, whereas, secondary ITP refers to immune-mediated thrombocytopenia with an underlying cause, including drug-induced, or associated with systemic illness (e.g., systemic lupus erythematosus, infection [e.g., HIV], immune deficiency [e.g., common variable immunodeficiency or autoimmune lymphoproliferative syndrome], and other causes).
Immune thrombocytopenia (ITP) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent Cases of Immune thrombocytopenia (ITP) in 7MM, Total Diagnosed Prevalent Cases of Immune thrombocytopenia (ITP) in 7MM, and Gender-specific Diagnosed Prevalent Cases of Immune thrombocytopenia (ITP) in 7MM) scenario of Immune thrombocytopenia (ITP) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.
According to this research, the total prevalent population of Immune Thrombocytopenia (ITP) in 7 major markets ranges from 180,498 in 2017. The number of Immune thrombocytopenia (ITP) cases in the 7MM is expected to increase during the study period of 2017-2028.
In addition, in 7MM, the total diagnosed prevalent cases is 147,174 in 2017. These cases are increased during study period (2017-2028).
In 2017, there were total 53,362 diagnosed prevalent cases of Immune thrombocytopenia (ITP) in the United States. Assessments as per the publisher's analysts show that the total diagnosed prevalent cases of Immune thrombocytopenia (ITP) are subjected to increase. Out of the total diagnosed cases, 49,640 cases account for adult ITP and 3,723 cases were diagnosed prevalence population in children in 2017.
Among the European countries, United Kingdom had the highest prevalent population of Immune thrombocytopenia (ITP) with 26,274 cases, followed by Italy which had a prevalent population of 18,604 in 2017. On the other hand, Spain had the lowest prevalent population of 12,207 in 2017.
Immune thrombocytopenia (ITP) Report Insights
Most of children with newly diagnosed ITP will develop chronic disease. Because of the high impact of ITP on a child's everyday life and activities, as well as to decide whether treatment has to be instituted to influence the clinical course of ITP, it is of clinical significance if the course of the disease could be predicted at time of diagnosis.
Our forecasting model has defined the prevalent population of Chronic Immune Thrombocytopenia (ITP) in children & adults. Chronic ITP patient inclusive of both primary ITP and secondary ITP. Approximately 70-75% of patient are refractory to first line therapies (corticosteroids/IVIG & others) and take second line therapies. As per the analysis, we have found that approximately 60-65% patients are refractory to second line treatment and take third line treatment.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Immune thrombocytopenia (ITP) - Disease Understanding
Immune thrombocytopenia (ITP), previously called immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder that occurs when the body attacks its own platelets and destroys them too quickly. ITP is a disorder that affects the overall number of blood platelets rather than their function.
Immune thrombocytopenia (ITP) is also categorized as primary and secondary based on the cause of the disease. ITP in the absence of other causes or disorders that may be associated with the thrombocytopenia is known as primary ITP, whereas, secondary ITP refers to immune-mediated thrombocytopenia with an underlying cause, including drug-induced, or associated with systemic illness (e.g., systemic lupus erythematosus, infection [e.g., HIV], immune deficiency [e.g., common variable immunodeficiency or autoimmune lymphoproliferative syndrome], and other causes).
Immune thrombocytopenia (ITP) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent Cases of Immune thrombocytopenia (ITP) in 7MM, Total Diagnosed Prevalent Cases of Immune thrombocytopenia (ITP) in 7MM, and Gender-specific Diagnosed Prevalent Cases of Immune thrombocytopenia (ITP) in 7MM) scenario of Immune thrombocytopenia (ITP) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.
According to this research, the total prevalent population of Immune Thrombocytopenia (ITP) in 7 major markets ranges from 180,498 in 2017. The number of Immune thrombocytopenia (ITP) cases in the 7MM is expected to increase during the study period of 2017-2028.
In addition, in 7MM, the total diagnosed prevalent cases is 147,174 in 2017. These cases are increased during study period (2017-2028).
In 2017, there were total 53,362 diagnosed prevalent cases of Immune thrombocytopenia (ITP) in the United States. Assessments as per the publisher's analysts show that the total diagnosed prevalent cases of Immune thrombocytopenia (ITP) are subjected to increase. Out of the total diagnosed cases, 49,640 cases account for adult ITP and 3,723 cases were diagnosed prevalence population in children in 2017.
Among the European countries, United Kingdom had the highest prevalent population of Immune thrombocytopenia (ITP) with 26,274 cases, followed by Italy which had a prevalent population of 18,604 in 2017. On the other hand, Spain had the lowest prevalent population of 12,207 in 2017.
Immune thrombocytopenia (ITP) Report Insights
- The report covers a descriptive overview of the Immune thrombocytopenia (ITP) Infections, explaining its causes, risk factors, pathophysiology, and diagnosis.
- Comprehensive insight has been provided into the epidemiology Immune thrombocytopenia (ITP) in the 7MM countries covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- Assesses growth opportunities in 7MM countries with respect to the patient population.
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation by Total diagnosed cases
- Adult Chronic ITP cases
- Gender-specific diagnosed prevalent cases
- Key assessments
- Patient Segmentation
- Disease Risk & Burden
- Risk of disease by Severity
Note: Product cover images may vary from those shown
1. Key Insights
2. Immune Thrombocytopenia (ITP) Patient Overview at a Glance
2.1. Patient Share (%) Distribution of Immune Thrombocytopenia (ITP) in 2017
2.2. Patient Share (%) Distribution of Immune Thrombocytopenia (ITP) in 2028
3. Immune Thrombocytopenia (ITP): Disease Background and Overview
3.1. Introduction
3.2. Etiology of Immune Thrombocytopenia (ITP)
3.3. Signs and Symptoms of Immune Thrombocytopenia (ITP)
3.4. Types of Immune Thrombocytopenia (ITP)
3.5. Pathophysiology of Immune Thrombocytopenia (ITP)
3.6. Pathogenesis of Immune Thrombocytopenia (ITP)
3.7. Genetic background and environmental factors related to ITP
3.8. Biomarkers associated with Immune Thrombocytopenia (ITP)
3.9. Diagnosis of Immune Thrombocytopenia
3.10. Diagnostic Guidelines of Immune Thrombocytopenia
3.10.1. 2011 Clinical Practice Guideline on the Evaluation and Management of Immune Thrombocytopenia (ITP)
3.10.2. The American Society of Hematology 2011 evidence-based practice guideline for Immune Thrombocytopenia
3.10.3. Japanese practice guidelines for newly diagnosed childhood idiopathic thrombocytopenic purpura
3.10.4. Spanish Society of Hematology and Hemotherapy: Guidelines for diagnosis, treatment and monitoring of the PTI
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Total Prevalent Patient Population of Immune Thrombocytopenia (ITP)
4.3. 7MM Diagnosed Prevalent Patient Population of Immune Thrombocytopenia
5. Country Wise-Epidemiology of Immune Thrombocytopenia (ITP)
5.1. United States Epidemiology
5.1.1. Assumptions and Rationale
5.1.2. Total Prevalent Cases of Immune Thrombocytopenia (ITP) in the United States
5.1.3. Diagnosed Prevalence of Immune Thrombocytopenia in the United States
5.1.4. Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in the United States
5.2. EU5 Epidemiology
5.2.1. Germany
5.2.1.1. Assumptions and Rationale
5.2.1.2. Total Prevalent Cases of Immune Thrombocytopenia (ITP) in Germany
5.2.1.3. Diagnosed Prevalence of Immune Thrombocytopenia in Germany
5.2.1.4. Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in Germany
5.2.2. France
5.2.2.1. Assumptions and Rationale
5.2.2.2. Total Prevalent Cases of Immune Thrombocytopenia (ITP) in France
5.2.2.3. Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in France
5.2.2.4. Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in France
5.2.3. Italy
5.2.3.1. Assumptions and Rationale
5.2.3.2. Total Prevalent Cases of Immune Thrombocytopenia in Italy
5.2.3.3. Diagnosed Prevalence of Immune Thrombocytopenia in Italy
5.2.3.4. Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in Italy
5.2.4. Spain
5.2.4.1. Assumptions and Rationale
5.2.4.2. Total Prevalent Cases of Immune Thrombocytopenia (ITP) in Spain
5.2.4.3. Diagnosed Prevalence of Immune Thrombocytopenia in Spain
5.2.4.4. Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in Spain
5.2.5. United Kingdom
5.2.5.1. Assumptions and Rationale
5.2.5.2. Total Prevalent Cases of Immune Thrombocytopenia (ITP) in the United Kingdom
5.2.5.3. Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in the United Kingdom
5.2.5.4. Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in the United Kingdom
5.3. Japan Epidemiology
5.3.1. Assumptions and Rationale
5.3.2. Total Prevalent Cases of Immune Thrombocytopenia (ITP) in Japan
5.3.3. Diagnosed Prevalence of Immune Thrombocytopenia in Japan
5.3.4. Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in Japan
6. Appendix
6.1. Report Methodology
7. Capabilities
8. Disclaimer
9. About the Publisher
List of Tables
Table 1 The role of infections in ITP pathogenesis
Table 2 Idiopathic Thrombocytopenic Purpura in Children: Newly Diagnosed ITP
Table 3 Total Prevalent Patient Population of Immune Thrombocytopenia in 7MM (2017-2028)
Table 4 Diagnosed Prevalent Patient Population of Immune Thrombocytopenia in the 7MM (2017-2028)
Table 5 Total Prevalent Population of Immune Thrombocytopenia in the United States (2017-2028)
Table 6 Diagnosed Prevalence of Immune Thrombocytopenia in the United States (2017-2028)
Table 7 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in the United States (2017-2028)
Table 8 Total Prevalent Population of Immune Thrombocytopenia in Germany (2017-2028)
Table 9 Diagnosed Prevalence of Immune Thrombocytopenia in Germany (2017-2028)
Table 10 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in Germany (2017-2028)
Table 11 Total Prevalent Population of Immune Thrombocytopenia in France (2017-2028)
Table 12 Diagnosed Prevalence of Immune Thrombocytopenia in France (2017-2028)
Table 13 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in France (2017-2028)
Table 14 Total Prevalent Population of Immune Thrombocytopenia in Italy (2017-2028)
Table 15 Diagnosed Prevalence of Immune Thrombocytopenia in Italy (2017-2028)
Table 16 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in Italy (2017-2028)
Table 17 Total Prevalent Population of Immune Thrombocytopenia in Spain (2017-2028)
Table 18 Diagnosed Prevalence of Immune Thrombocytopenia in Spain (2017-2028)
Table 19 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in Spain (2017-2028)
Table 20 Total Diagnosed Prevalent Population of Immune Thrombocytopenia (ITP) in the United Kingdom (2017-2028)
Table 21 Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in the United Kingdom (2017-2028)
Table 22 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in the United Kingdom (2017-2028)
Table 23 Total Prevalent Population of Immune Thrombocytopenia (ITP) in Japan (2017-2028)
Table 24 Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in Japan (2017-2028)
Table 25 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in Japan (2017-2028)
List of Figures
Figure 1 Differences in B cell and T cell mechanisms in immune thrombocytopenia (ITP)
Figure 2 Signs and Symptoms of Immune Thrombocytopenia
Figure 3 Classification of Immune Thrombocytopenia (ITP)
Figure 4 ITP International Working Group proposed definitions of disease
Figure 5 Pathophysiology of cITP
Figure 6 Cellular pathogenic mechanisms in immune thrombocytopenia
Figure 7 Immune thrombocytopenia pathogenesis
Figure 8 Total Prevalent Patient Population of Immune Thrombocytopenia in 7MM (2017-2028)
Figure 9 Diagnosed Prevalent Patient Population of Immune Thrombocytopenia in the 7MM (2017-2028)
Figure 10 Total Prevalent Cases of Immune Thrombocytopenia in the United States (2017-2028)
Figure 11 Diagnosed Prevalence of Immune Thrombocytopenia in the United States (2017-2028)
Figure 12 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in the United States (2017-2028)
Figure 13 Total Prevalent Cases of Immune Thrombocytopenia in Germany (2017-2028)
Figure 14 Diagnosed Prevalence of Immune Thrombocytopenia in Germany (2017-2028)
Figure 15 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in Germany (2017-2028)
Figure 16 Total Prevalent Cases of Immune Thrombocytopenia in France (2017-2028)
Figure 17 Diagnosed Prevalence of Immune Thrombocytopenia in France (2017-2028)
Figure 18 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in France (2017-2028)
Figure 19 Diagnosed Prevalence of Immune Thrombocytopenia in Italy (2017-2028)
Figure 20 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in Italy (2017-2028)
Figure 21 Total Prevalent Cases of Immune Thrombocytopenia in Spain (2017-2028)
Figure 22 Diagnosed Prevalence of Immune Thrombocytopenia in Spain (2017-2028)
Figure 23 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in Spain (2017-2028)
Figure 24 Total Prevalent Cases of Immune Thrombocytopenia in the United Kingdom (2017-2028)
Figure 25 Diagnosed Prevalence of Immune Thrombocytopenia in the United Kingdom (2017-2028)
Figure 26 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in the United Kingdom (2017-2028)
Figure 27 Total Prevalent Cases of Immune Thrombocytopenia (ITP) in Japan (2017-2028)
Figure 28 Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in Japan (2017-2028)
Figure 29 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in Japan (2017-2028)
2. Immune Thrombocytopenia (ITP) Patient Overview at a Glance
2.1. Patient Share (%) Distribution of Immune Thrombocytopenia (ITP) in 2017
2.2. Patient Share (%) Distribution of Immune Thrombocytopenia (ITP) in 2028
3. Immune Thrombocytopenia (ITP): Disease Background and Overview
3.1. Introduction
3.2. Etiology of Immune Thrombocytopenia (ITP)
3.3. Signs and Symptoms of Immune Thrombocytopenia (ITP)
3.4. Types of Immune Thrombocytopenia (ITP)
3.5. Pathophysiology of Immune Thrombocytopenia (ITP)
3.6. Pathogenesis of Immune Thrombocytopenia (ITP)
3.7. Genetic background and environmental factors related to ITP
3.8. Biomarkers associated with Immune Thrombocytopenia (ITP)
3.9. Diagnosis of Immune Thrombocytopenia
3.10. Diagnostic Guidelines of Immune Thrombocytopenia
3.10.1. 2011 Clinical Practice Guideline on the Evaluation and Management of Immune Thrombocytopenia (ITP)
3.10.2. The American Society of Hematology 2011 evidence-based practice guideline for Immune Thrombocytopenia
3.10.3. Japanese practice guidelines for newly diagnosed childhood idiopathic thrombocytopenic purpura
3.10.4. Spanish Society of Hematology and Hemotherapy: Guidelines for diagnosis, treatment and monitoring of the PTI
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Total Prevalent Patient Population of Immune Thrombocytopenia (ITP)
4.3. 7MM Diagnosed Prevalent Patient Population of Immune Thrombocytopenia
5. Country Wise-Epidemiology of Immune Thrombocytopenia (ITP)
5.1. United States Epidemiology
5.1.1. Assumptions and Rationale
5.1.2. Total Prevalent Cases of Immune Thrombocytopenia (ITP) in the United States
5.1.3. Diagnosed Prevalence of Immune Thrombocytopenia in the United States
5.1.4. Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in the United States
5.2. EU5 Epidemiology
5.2.1. Germany
5.2.1.1. Assumptions and Rationale
5.2.1.2. Total Prevalent Cases of Immune Thrombocytopenia (ITP) in Germany
5.2.1.3. Diagnosed Prevalence of Immune Thrombocytopenia in Germany
5.2.1.4. Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in Germany
5.2.2. France
5.2.2.1. Assumptions and Rationale
5.2.2.2. Total Prevalent Cases of Immune Thrombocytopenia (ITP) in France
5.2.2.3. Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in France
5.2.2.4. Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in France
5.2.3. Italy
5.2.3.1. Assumptions and Rationale
5.2.3.2. Total Prevalent Cases of Immune Thrombocytopenia in Italy
5.2.3.3. Diagnosed Prevalence of Immune Thrombocytopenia in Italy
5.2.3.4. Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in Italy
5.2.4. Spain
5.2.4.1. Assumptions and Rationale
5.2.4.2. Total Prevalent Cases of Immune Thrombocytopenia (ITP) in Spain
5.2.4.3. Diagnosed Prevalence of Immune Thrombocytopenia in Spain
5.2.4.4. Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in Spain
5.2.5. United Kingdom
5.2.5.1. Assumptions and Rationale
5.2.5.2. Total Prevalent Cases of Immune Thrombocytopenia (ITP) in the United Kingdom
5.2.5.3. Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in the United Kingdom
5.2.5.4. Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in the United Kingdom
5.3. Japan Epidemiology
5.3.1. Assumptions and Rationale
5.3.2. Total Prevalent Cases of Immune Thrombocytopenia (ITP) in Japan
5.3.3. Diagnosed Prevalence of Immune Thrombocytopenia in Japan
5.3.4. Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in Japan
6. Appendix
6.1. Report Methodology
7. Capabilities
8. Disclaimer
9. About the Publisher
List of Tables
Table 1 The role of infections in ITP pathogenesis
Table 2 Idiopathic Thrombocytopenic Purpura in Children: Newly Diagnosed ITP
Table 3 Total Prevalent Patient Population of Immune Thrombocytopenia in 7MM (2017-2028)
Table 4 Diagnosed Prevalent Patient Population of Immune Thrombocytopenia in the 7MM (2017-2028)
Table 5 Total Prevalent Population of Immune Thrombocytopenia in the United States (2017-2028)
Table 6 Diagnosed Prevalence of Immune Thrombocytopenia in the United States (2017-2028)
Table 7 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in the United States (2017-2028)
Table 8 Total Prevalent Population of Immune Thrombocytopenia in Germany (2017-2028)
Table 9 Diagnosed Prevalence of Immune Thrombocytopenia in Germany (2017-2028)
Table 10 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in Germany (2017-2028)
Table 11 Total Prevalent Population of Immune Thrombocytopenia in France (2017-2028)
Table 12 Diagnosed Prevalence of Immune Thrombocytopenia in France (2017-2028)
Table 13 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in France (2017-2028)
Table 14 Total Prevalent Population of Immune Thrombocytopenia in Italy (2017-2028)
Table 15 Diagnosed Prevalence of Immune Thrombocytopenia in Italy (2017-2028)
Table 16 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in Italy (2017-2028)
Table 17 Total Prevalent Population of Immune Thrombocytopenia in Spain (2017-2028)
Table 18 Diagnosed Prevalence of Immune Thrombocytopenia in Spain (2017-2028)
Table 19 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in Spain (2017-2028)
Table 20 Total Diagnosed Prevalent Population of Immune Thrombocytopenia (ITP) in the United Kingdom (2017-2028)
Table 21 Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in the United Kingdom (2017-2028)
Table 22 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in the United Kingdom (2017-2028)
Table 23 Total Prevalent Population of Immune Thrombocytopenia (ITP) in Japan (2017-2028)
Table 24 Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in Japan (2017-2028)
Table 25 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in Japan (2017-2028)
List of Figures
Figure 1 Differences in B cell and T cell mechanisms in immune thrombocytopenia (ITP)
Figure 2 Signs and Symptoms of Immune Thrombocytopenia
Figure 3 Classification of Immune Thrombocytopenia (ITP)
Figure 4 ITP International Working Group proposed definitions of disease
Figure 5 Pathophysiology of cITP
Figure 6 Cellular pathogenic mechanisms in immune thrombocytopenia
Figure 7 Immune thrombocytopenia pathogenesis
Figure 8 Total Prevalent Patient Population of Immune Thrombocytopenia in 7MM (2017-2028)
Figure 9 Diagnosed Prevalent Patient Population of Immune Thrombocytopenia in the 7MM (2017-2028)
Figure 10 Total Prevalent Cases of Immune Thrombocytopenia in the United States (2017-2028)
Figure 11 Diagnosed Prevalence of Immune Thrombocytopenia in the United States (2017-2028)
Figure 12 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in the United States (2017-2028)
Figure 13 Total Prevalent Cases of Immune Thrombocytopenia in Germany (2017-2028)
Figure 14 Diagnosed Prevalence of Immune Thrombocytopenia in Germany (2017-2028)
Figure 15 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in Germany (2017-2028)
Figure 16 Total Prevalent Cases of Immune Thrombocytopenia in France (2017-2028)
Figure 17 Diagnosed Prevalence of Immune Thrombocytopenia in France (2017-2028)
Figure 18 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in France (2017-2028)
Figure 19 Diagnosed Prevalence of Immune Thrombocytopenia in Italy (2017-2028)
Figure 20 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in Italy (2017-2028)
Figure 21 Total Prevalent Cases of Immune Thrombocytopenia in Spain (2017-2028)
Figure 22 Diagnosed Prevalence of Immune Thrombocytopenia in Spain (2017-2028)
Figure 23 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in Spain (2017-2028)
Figure 24 Total Prevalent Cases of Immune Thrombocytopenia in the United Kingdom (2017-2028)
Figure 25 Diagnosed Prevalence of Immune Thrombocytopenia in the United Kingdom (2017-2028)
Figure 26 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in the United Kingdom (2017-2028)
Figure 27 Total Prevalent Cases of Immune Thrombocytopenia (ITP) in Japan (2017-2028)
Figure 28 Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in Japan (2017-2028)
Figure 29 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in Japan (2017-2028)
Note: Product cover images may vary from those shown
